Reimbursed Care Access in Sri Lanka

Currently classified as a strictly controlled substance under Sri Lanka’s Poisons/Opium/Dangerous Drugs legislation with no authorised medical or reimbursed use outside of approved clinical research. Law enforcement has actively interdicted shipments and local seizures of "magic mushrooms" have been reported, reflecting active enforcement of prohibition. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use or public reimbursement outside of approved clinical research. Sri Lankan customs and police have reported seizures of MDMA/ecstasy in recent enforcement operations. # #

There is no evidence of a licensed, nationally reimbursed esketamine (SPRAVATO®) programme or NMRA marketing authorisation publicly listed for esketamine in Sri Lanka; therefore esketamine is not part of routine publicly reimbursed mental‑health care and would not be available except via an import licence/regulated special supply route or an authorised clinical trial if such a trial were approved by NMRA/ethics authorities. The NMRA is the national regulator for medicines and clinical trials in Sri Lanka and controls marketing authorisations and clinical trial approvals. Clinicians could theoretically seek special import/compassionate pathways under NMRA rules, but there is no routine, reimbursed esketamine pathway in national practice as of the available public records. # #

Ketamine is a legally registered and used anaesthetic/analgesic in Sri Lankan hospitals and is part of standard perioperative care; there is an established clinical and academic literature documenting ketamine anaesthesia and hospital perioperative/postoperative use in Sri Lanka. Use as an anaesthetic and for analgesia is overseen by hospital pharmacy/anaesthesia services and the NMRA/Cosmetics, Devices & Drugs Acts regulate medicinal supply. # #

Off‑label/experimental uses of intravenous low‑dose ketamine for treatment‑resistant depression and difficult‑to‑treat depression have appeared in local clinical reports and centre‑level studies; such uses tend to be delivered in tertiary hospitals or private clinics on a case‑by‑case basis and are not part of a nationally funded reimbursed mental‑health programme. Where ketamine is used for psychiatric/adjunctive purposes, treatment is typically out‑of‑pocket or provided by private facilities; there is no public, nationwide reimbursement programme covering ketamine infusions for depression analogous to established national reimbursement for registered medicines. Local clinicians and teaching hospitals have published work on IV ketamine for depression and postoperative analgesia, demonstrating clinical use and research interest, but formal national reimbursement pathways for psychiatric ketamine therapy are not documented in public NMRA or health ministry resources. # #

Regulatory & enforcement context: the Poisons/Opium/Dangerous Drugs legal framework and the NDDCB/NMRA coordinate control over dangerous drugs; manufacturing, supply, import/export and unauthorised possession/trafficking are criminalised, and special licences or authorised hospital supply chains are required for legitimate medical ketamine use. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of nationally sanctioned DMT medical programmes or reimbursement, and possession, import or distribution is subject to the Poisons/Opium/Dangerous Drugs legal framework. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No authorised clinical or reimbursed programmes exist in Sri Lanka. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognised, regulated ibogaine therapy or reimbursement pathway in Sri Lanka. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (ayahuasca) are therefore treated as prohibited unless part of an authorised, regulated research protocol. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no national medical or reimbursement pathway for mescaline in Sri Lanka. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamines such as 2C‑series compounds, where present in schedules or covered by broad prohibitions, are treated as illegal and subject to enforcement actions. #